Cel-Sci (United States)
American biotechnology company
CVM Nasdaq
ISIN US1508377066 SEC CIK 725363 LEI 549300FIWOFSETIVMI17
Follow Cel-Sci (United States)
Weekly email: filings, results
Net income
−$5.7M
−0% vs same quarter last year
EPS, diluted
−$0.47
+65.4% vs same quarter last year
Operating cash flow
−$4M
−2.3% vs same quarter last year
Operating income
−$5.6M
−1.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$25.4M |
| FY24 | - | −$26.9M |
| FY23 | - | −$32.4M |
| FY22 | - | −$36.7M |
| FY21 | - | −$36.4M |
| FY20 | - | −$30.3M |
| FY19 | - | −$22.1M |
| FY18 | - | −$31.8M |
| FY17 | - | −$14.4M |
| FY16 | - | −$11.5M |
| FY15 | - | −$34.7M |
| FY14 | $264K | −$27.4M |
| FY13 | $159.6K | −$9.2M |
| FY12 | $254.6K | −$15.5M |
| FY11 | $956.2K | −$25.7M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | −9721.4% | −10359.6% |
| FY13 | −12450.1% | −5746.8% |
| FY12 | −6772.3% | −6078.8% |
| FY11 | −1881% | −2689.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$17.2M |
| FY24 | −$18.9M |
| FY23 | −$23.2M |
| FY22 | −$18.9M |
| FY21 | −$27.8M |
| FY20 | −$17.9M |
| FY19 | −$16.5M |
| FY18 | −$13.4M |
| FY17 | −$13.8M |
| FY16 | −$23.1M |
| FY15 | −$23.9M |
| FY14 | −$23M |
| FY13 | −$13.7M |
| FY12 | −$12.2M |
| FY11 | −$22.8M |
- Cel-Sci (United States)
- Healthcare median
Show the numbers
| Year | Cel-Sci (United States) | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | −10359.6% | −35.5% |
| FY13 | −5746.8% | −37.1% |
| FY12 | −6078.8% | −29.1% |
| FY11 | −2689.1% | −27.9% |